Patient Home Monitoring (PHM) Announces Monthly Progress Report for May 2012

Patient Home Monitoring Corp. (TSX VENTURE:PHM), a company focused on in-home
cardiology healthcare services, today announces its monthly progress report on
its business as it expands into becoming a provider of multiple in-home
healthcare services for cardiology patients.


PHM continues to build its platform for management of clinical operations. In
the past quarter, PHM has rolled out a state-of-the-art software application for
linking in-home data and launched its National Dosing Support Center. In May and
June, PHM management has been assessing various in-home services suitable for
its cardiology market patients to expand its offering in the following
underserved large markets:




--  Heart-healthy weight loss programs 
--  Corporate wellness services 
--  Sleep monitoring 
--  Overnight event monitoring 
--  Residentialist services (House calls) 
--  Hospital readmission reduction programs 
--  In-home monitoring for health plan patients 
--  Alert programs 
--  Smart phone technology services support



PHM management plans to finalize the decision for its next initiative into a new
market in the coming months, as the first step in a process of leveraging its
platform to cardiologists to achieve complementary offerings for broader patient
management. PHM is assessing each area based upon criteria including low
marginal costs, low capital costs, high levels of demand from the current
patient base and regulatory risks.


Monthly Growth in Blood Thinner Patients 

As PHM begins to focus upon a broader market offering, PHM will shift announcing
monthly meter shipments and INR tests to each quarter, starting in June 2012.
PHM plans to continue to invest in this high margin business and expects
continued growth from the business. As PHM expands into multiple revenue lines,
management will present appropriate key performance indicators. PHM has grown
monthly by adding patients on blood thinners to their long-term annuity stream
business. 




1.  Monthly Growth. PHM generates a recurring revenue stream from enrolled
    testers by recording a weekly INR value and transmitting the information
    to the patient's healthcare provider. 
    --  In May of 2012, PHM recorded 9,335 INR tests. 
    --  In May of 2012, PHM shipped 115 meters. Understanding how many
        meters were shipped to newly enrolled patients each month is
        relevant for analyzing growth because shipment of a meter is a
        prerequisite to performing INR(1) tests eligible for
        reimbursement(2).



"As announced last month, we are using this opportunity in the young life of PHM
to expand into new areas of service that will benefit our current patients and
referral doctor groups," said Dr. Jaime Gerber, PHM's CEO. "We continue to
believe in the power of our platform and now we will leverage our investment in
this platform to enter one or more of these exciting growth markets. This will
give us multiple revenue streams and will help PHM take advantage of the loyalty
it has earned from current cardiology groups." 


"We believe that continued high quality work in our blood thinner monitoring
services and clinic management is key to our success in new markets," continued
Dr. Gerber. "The local clinics will be the foundation for providing new and
innovative services to our existing patients and referral groups."


About PHM 

PHM is a healthcare services company focused on providing home-based monitoring
services and supplies for cardiology patients. PHM's entry-point service
monitors patients on blood thinner medications such as Coumadin(r) or warfarin.
Medicare recently expanded reimbursement for this in-home service. PHM has a
unique value proposition to cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This unique,
systemized approach creates an opportunity for physician groups to operate more
efficiently, increasing revenue to their clinic while providing a higher
standard of care for patients. PHM plans to lever its position as a value-added
service provider to expand into other home-based services for these patients and
their referring physicians. 


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, changes in US healthcare laws, coverage or budgets,
dependence on few payors, possible new drug discoveries, a novel business model,
dependence on key suppliers, granting of permits and licenses in a highly
regulated business, competition, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected. 


(1) International normalized ratio ("INR") tests are used as measures of current
and future sales performance. Please refer to the "Non-GAAP Measures" section of
PHM's MD&A for further discussion on these operational measures. 


(2) Management does not mean to suggest or imply that shipment of meters is
equivalent to revenue. Meter shipment is a prerequisite, but not a guarantee, of
revenue. Management does not propose meter shipments as a non-GAAP financial
measurement, because there is no simple reconciliation between meter shipment
and GAAP revenue.